LAUSR

OBJECTIVE To determine if use of the hematuria risk index can reduce testing and cost, while maintaining equivalent lesion detection in patients with asymptomatic microscopic hematuria. MATERIALS AND METHODS Retrospective cohort study of 1049 patients at single institution. Hematuria risk index score was calculated based on clinical factors including age, sex, smoking history and degree of hematuria for each patient along with evaluation studies performed and total number of tumors discovered. Cost benefit analysis was performed based on published Medicare averages. RESULTS Tumor detection rate in overall, low risk, and moderate risk groups were: 1.2%, 0%, and 2.96% at a total cost of $408,376. When low risk group is not screened cost decreases to $166,252 with no lesions missed. The cost to discover one lesion/cancer in the overall group was $34,031.3, the cost to find one high grade clinically significant lesion/cancer was $136,125.3 for the overall group. When the low risk group was removed the cost to find a high grade clinically significant lesion/cancer decreased to $55,417.3 without missing any significant lesions. Ultrasound may be utilized instead of computed tomography with minimal loss of lesion detection in select moderate risk patients. CONCLUSION None of the low risk hematuria risk patients were diagnosed with any lesions, as such these patients may not need an evaluation. Furthermore, by utilizing a risk stratified approach to the assessment of AMH health care costs can be significantly decreased with limited negative consequences in terms of lesion detection.